Key Highlights
- AffyImmune Therapeutics announces the appointment of Rick Rutter, Ph.D., and Jorge Nieva, M.D., to its Board of Directors.
- Appointments bolster AffyImmune’s AIC100 CAR T cell therapy development for advanced thyroid cancers and non-small cell lung cancer (NSCLC).
- Rutter and Nieva bring decades of experience in CMC regulatory strategy and clinical oncology.
- AffyImmune’s AIC100 is nearing completion of Phase 1 trials for thyroid cancer and moving toward Phase 2 for NSCLC.
Source: Business Wire
Notable Quotes
- “I am delighted to join AffyImmune’s Board and to work with the management team to bring industry-best CMC and supply chain practices, and ready AIC100 for registrational trials and commercial launch.” — Rick Rutter, Ph.D., Former Executive Vice President, Biotherapeutics Pharmaceutical Sciences at Pfizer; Expert Consultant
- “Joining AffyImmune’s Board of Directors is an exciting opportunity to contribute to the expansion of AIC100 beyond advanced thyroid cancers, into larger indications such as NSCLC.” — Jorge Nieva, M.D., Associate Professor of Clinical Medicine at Keck School of Medicine, University of Southern California
SoHC's Take
AffyImmune’s strategic appointments of Rick Rutter, Ph.D., and Jorge Nieva, M.D., signal a pivotal moment for the company as it progresses its innovative CAR T cell therapy, AIC100, toward advanced clinical trials. These new board members not only enhance the company’s expertise in regulatory strategy and oncology but also strengthen its ability to address significant unmet medical needs in thyroid cancer and NSCLC. This expansion marks a crucial step for AffyImmune as it readies AIC100 for commercialization, advancing toward transforming solid tumor treatment landscapes.
Heading
Key Highlights CalmWave closes a $5.25M financing round led by Third Prime with contributions from Catalyst by Wellstar, Silver Circle, and ...
Key Highlights Alice Koehler appointed Managing Director of OMRON Healthcare North America. Koehler brings 25+ years of global experience in ...
Key Highlights Koda Health introduces Kidney Action Planning to support Chronic Kidney Disease (CKD) management with cutting-edge tools. Features include gamified patient ...
Key Highlights Northwell Health’s Aging Revolution Summit will take place virtually and in-person in NYC on December 3, 2024. Key themes: Therapeutics, ...
Key Highlights $5M Series A funding led by Empactful Capital to fuel growth and innovation. Investment will support product development, strategic accounts, and new market ...
Key Highlights New Lantern raises $19M Series A funding, led by Benchmark, totaling $23M raised to date. Platform automates 25% of ...
